Dr. Ilia Kirshner is a physician in hematology and medical oncology at Sourasky Medical Center. He participated in the phase III clinical trial for castrate-resistant prostate cancer treatment. This research compared the efficacy of enzalutamide against combined abiraterone therapy.
Specialization & Clinical Focus
Dr. Kirshner treats blood disorders and cancers at Sourasky Medical Center. He treats malignant conditions and bone marrow diseases. Furthermore, he provides consultations for patients with chronic and acute hematologic issues.
The doctor treats several specific conditions:
- Myeloma — a type of blood cancer that develops in plasma cells in the bone marrow
- Thrombocytopenia — a condition characterized by low blood platelet counts which can cause bruising and bleeding
- Aplastic anemia — a rare condition where the body stops producing enough new blood cells
- Follicular lymphoma — a type of slow-growing non-Hodgkin lymphoma that affects white blood cells
Education & Training
Dr. Kirshner completed medical training at several institutions in the United States.
- 1995 – Fellowship in hematology, Montefiore Medical Center
- 1994 – Fellowship in medical oncology, Montefiore Medical Center
- 1990 – Residency in internal medicine, St. Luke's-Roosevelt Hospital Center
- 1987 – Doctor of Medicine, University of Medicine and Dentistry of New Jersey
- 1983 – Bachelor of Arts, Brandeis University
Research Contributions
The physician participates in oncology research and clinical trials. He investigates pharmaceutical protocols for advanced prostate cancer. This work helps develop hormonal therapy combinations. He also focuses on survival outcomes for patients with treatment-resistant tumors.